GSK-3 Inhibitor

GSK-3 Inhibitors (51):

Cat. No.	Product Name	Effect	Purity

HY-153089

GSK3-IN-3	Inhibitor	98.80%
GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC₅₀ value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA.

HY-12524

Bikinin	Inhibitor	99.96%
Bikinin is a non-steroidal, ATP-competitive inhibitor of plant GSK-3/Shaggy-like kinases and activates BR (brassinosteroids) signaling.

HY-103647

K00546	Inhibitor	98.08%
K00546 is a potent CDK1 and CDK2 inhibitor with IC₅₀s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC₅₀s of 8.9 nM and 29.2 nM, respectively.

HY-103221

MeBIO	Inhibitor	≥98.0%
MeBIO is a potent AhR (aryl hydrocarbon receptor) agonist, with IC₅₀ of 44 μM (GSK-3) and 55 μM (CDK1/cyclin B), respectively.

HY-128879A

VP3.15 dihydrobromide	Inhibitor	98.01%
VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC₅₀s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 dihydrobromide has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS).

HY-40294

Indazole	Inhibitor	99.72%
Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases.

HY-13973A

GSK-3 inhibitor 1	Inhibitor	99.89%
GSK-3 inhibitor 1 (compound core 3) is a GSK-3 inhibitor that induces stem/progenitor cell self-renewal (e.g. induces stem/progenitor cell proliferation while maintaining the ability to differentiate into tissue cells in the progeny).

HY-144290

ARN25068	Inhibitor	99.66%
ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation.

HY-117822

BRD0209	Inhibitor	99.56%
BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC₅₀ = 19 nM; GSK3β IC₅₀ = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics (K_i = 4.2 nM, respectively). BRD0209 is a tricyclic pyrazolotetrahydroquinolinone compound. BRD0209 has the potential for the research of mood disorder diseases.

HY-107815

CHIR 98024	Inhibitor	98.08%
CHIR 98024 (Compound L) is a glycogen synthase kinase 3 (GSK3) inhibitor with an EC₅₀ of 0.2566 μM.

HY-112392

GSK-3 Inhibitor XIII	Inhibitor	98.61%
GSK-3 Inhibitor XIII is a potent and ATP-competitive GSK-3 inhibitor with a K_i of 24 nM.

HY-126144A

(E/Z)-GSK-3β inhibitor 1	Inhibitor	99.03%
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM.

HY-Q48328

GSK3-IN-1	Inhibitor	99.86%
GSK3-IN-1 (compound 11) is a GSK-3 inhibitor with an IC₅₀ value of 12 μM. GSK3-IN-1 can be used in the research of diabetes.

HY-10182R

Laduviglusib (Standard)	Inhibitor
Laduviglusib (Standard) is the analytical standard of Laduviglusib. Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy.

HY-N12625

(R)-(+)-O-Demethylbuchenavianine	Inhibitor	98.67%
(R)-(+)-O-Demethylbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine inhibits CDK1, CDK5, glycogen synthase kinase-3 (GSK3), cdc2-like kinase (CLK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), with IC₅₀s of 1.1, 0.95, >10, >10 and >10 μM, respectively.

HY-134622

GSK-3/CDK5/CDK2-IN-1	Inhibitor	98.10%
GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, cdk2, and GSK-3 extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 can be used for the research of cancer, and neurodegenerative diseases.

HY-112388

GSK-3b Inhibitor XI	Inhibitor	99.10%
GSK3β inhibitor XI is a potent inhibitor of glycogen synthase kinase 3β (GSK3β; Ki=25 nM). It is selective for GSK3β over a panel of 79 kinases at a concentration of 10 μM. GSK3β inhibitor XI inhibits GSK3β in HEK293 cells (EC₅₀=32 nM).

HY-10096

TCS2002	Inhibitor	99.8%
TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3β inhibitor with the IC₅₀ of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease.

HY-126771

Chrysomycin A	Inhibitor	≥98.0%
Chrysomycin A (Chr-A), an antibiotic, can be obtained from Streptomyces. Chrysomycin A exhibits antitumor and anti-tuberculous and MRSA activities. As for glioblastoma, Chrysomycin A inhibits the proliferation, migration, and invasion of cancer cells through the Akt/GSK-3β/β-catenin signaling pathway.

HY-B0320AR

Cromolyn sodium (Standard)	Inhibitor
Cromolyn (sodium) (Standard) is the analytical standard of Cromolyn (sodium). This product is intended for research and analytical applications. Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic agent. Cromolyn sodium is a GSK-3β inhibitor with an IC₅₀ of 2.0 μM.

Name
Email *

	Sorry, but the email address you supplied was invalid.